All figures are in US$ million unless stated otherwise	2018-19  Constant Currency(1)	2018-19  Reported(2)	2017-18  Reported	2016-17  Reported	2015-16  Reported	2014-15  Reported
Total Operating Revenue	8,757	8,539	7,915	6,947	6,115	5,612
Sales Revenue	8,418	8,205	7,588	6,616	5,909	5,459
R&D Investment	853	832	702	667	614	463
Profit before Income Tax Expense	2,465	2,341	2,281	1,690	1,556	1,714
Net profit after tax	2,015	1,919	1,729	1,337	1,242	1,379
Net cash inflow from Operating Activities		1,644	1,902	1,247	1,179	1,364
Capital investment		992	992	861	566	414
Return on Invested Capital (%)		24.3	25.9	24.5	26.8(3)	31.70
Basic earnings per share ($)		4.236	3.822	2.937	2.689	2.923
Dividend per share ($)		1.850	1.720	1.360	1.26	1.24

(1) Constant currency removes the impact of exchange rate movements, facilitating comparability of operational performance. For further details please refer to CSL’s Financial Statements for the Full Year ended 2019 (Directors’ Report).
(2) The Group’s reported results are in accordance with the Australian Equivalents to International Financial Reporting Standards (A-IFRS).
(3) 2016 figure includes the gain on acquisition of Novartis’ global influenza vaccine business of US$176.1 million.